Zurück zur Übersicht
| Veterinary and comparative oncology. 2018 Aug 22. doi: 10.1111/vco.12440 |
| Comparative Oncology: the Paradigmatic Example of Canine and Human Mast Cell Neoplasms. |
| Willmann M1, Hadzijusufovic E2, Hermine O3, Dacasto M4, Marconato L5, Bauer K6, Peter B7, Gamperl S8, Eisenwort G9, Jensen-Jarolim E10, Müller M11, Arock M12, Vail DM13, Valent P14 |
 Author information
|
|
Abstract In humans, advanced mast cell (MC) neoplasms are rare malignancies with a poor prognosis. Only a few preclinical models are available and current treatment options are limited. In dogs, MC neoplasms are the most frequent malignant skin tumors. Unlike low-grade MC neoplasms, high-grade MC disorders usually have a poor prognosis with short survival. In both species, neoplastic MCs display activating KIT mutations which are considered to contribute to disease evolution. Therefore, tyrosine kinase inhibitors against KIT have been developed. Unfortunately, clinical responses are unpredictable and often transient, which remains a clinical challenge in both species. Therefore, current efforts focus on the development of new improved treatment strategies. The field of comparative oncology may assist in these efforts and accelerate human and canine research regarding diagnosis, prognostication and novel therapies. In this article, we review the current status of comparative oncology approaches and perspectives in the field of mast cell neoplasms. This article is protected by copyright. All rights reserved. |
|
This article is protected by copyright. All rights reserved. |
|
KEYWORDS: CD25, CD30, Canine Mast cell neoplasm, KIT mutations, tryptase |
|
Publikations ID: 30136349 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
